fda compounded semaglutide enforcement news The is drawing a harder line on weight loss drug marketing. In the May–June 2026 issue of Dispense Times, this article breaks down key violations cited in recent FDA Are compounded GLP-1 drugs as

Bottles of 30 NDC 21695-746-30 Bottles of 90 NDC 21695-746-90 Glimepiride tablets USP, 4 mg are blue, oval, flat bevelled edged, uncoated tablets embossed RDY on one side and 322 separating 3 and 22 with bisect line scoring on the other side and are supplied in bottles of 30, 60 and 90

Tata B, Mimouni NEH, Barbotin AL, Malone SA, Loyens A, Pigny P, et al

Great product and company

Impact of Liraglutide on Amylase, Lipase, and Acute Pancreatitis in Participants with Overweight/Obesity and Normoglycemia, Prediabetes, or Type 2 Diabetes: Secondary Analyses of Pooled Data from the SCALE Clinical Development Program

When we understand the mechanism, we can better tailor the intervention

With PA approved on Tier 3, expect a copay of $40 to $100 per month for commercial plans, depending on benefit design